BioSpace News Archive

F2G Ltd. today announced that the Company’s chief executive officer, Francesco Lavino will provide a corporate overview at Biotech Showcase™ 2023 taking place in San Francisco, California, from January 9-11, 2023.

Arbutus Biopharma Corporation today announced its 2023 corporate objectives and provided a financial update.

Frontier Medicines Corporation announced the selection of its first development candidate, FMC-376, an oral, covalent small-molecule inhibitor that selectively targets both active (GTP-bound) and inactive (GDP-bound) conformations of KRASG12C.

Biogen Inc. (Nasdaq: BIIB) announced that Priya Singhal, M.D., M.P.H., currently Head of Global Safety and Regulatory Sciences and Interim Head of Research & Development, has been promoted to Executive Vice President, Head of Development, following a decision to separate Research and Development into two distinct functions that will both report directly to the CEO.

Curative Biotechnology Inc. announced today that it has successfully completed its Investigational New Drug (IND) enabling Tolerance and Toxicology Study of Metformin HCL Solution by Topical Instillation (eye drops) in Rabbits.

Reset Pharmaceuticals, Inc., a privately held biotechnology company focused on the development of innovative treatments to address mental health indications related to life-altering diseases, announces that Innes Meldrum has been appointed President and Chief Executive Officer.

Ventyx Biosciences, Inc. announced that it will host an R&D event on Thursday, January 26, 2023 in New York City from 9-11:30 a.m. ET.

AUM Biosciences Pte. Ltd. announced that the U.S. Food and Drug Administration has granted a Rare Pediatric Disease Designation for its product candidate, AUM302, a potential first-in-class oral kinase inhibitor that targets not only PI3K, but also key resistance mechanisms such as PIM and mTOR, for the treatment of neuroblastoma.

Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) today announced that Jerry Durso, President and Chief Executive Officer, will give a corporate presentation at the J.P. Morgan 41st Annual Healthcare Conference.

Invectys, Inc. “Invectys” announced that Praveen Tyle, Ph.D., President and CEO of Invectys, will participate in the 2023 edition of the JP Morgan Healthcare Meeting on January 9-12, 2023.